The range of anticancer drugs for the treatment of non-small cell lung cancer has changed significantly in recent years due to the advent of immunotherapy and targeted drugs targeting driver mutations. Today it has become possible to prescribe more effective and less toxic treatment to patients than chemotherapy. This review focuses on the ceritinib, 2nd generation ALK inhibitor. Data from clinical studies confirming the effectiveness of the drug and the feasibility of its use both in pre-treated patients and in patients with newly diagnosed metastatic ALK-positive non-small cell lung cancer are presented.

Keywords: ceritinib, ALK, non-small cell lung cancer, targeted therapy